Research Paper Volume 15, Issue 14 pp 6757—6773
PARP10 is highly expressed and associated with inferior outcomes in acute myeloid leukemia
Figure 3. Association of PARP10 expression with TP53 mutation status and risk classifications in AML patients. (A) PARP10 expression difference between AML patients with wildtype and mutant TP53. Statistical significance was estimated using an unpaired t test. (B) PARP10 expression differences among patients with good-risk, intermediate-risk, and poor-risk ENL classifications. (C) PARP10 expression difference among patients with good-risk, intermediate-risk, and poor-risk cytogenetic classifications. Statistical significance was estimated using the Kruskal-Wallis test.